Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Ongoing drug price revisions, higher manufacturing costs, a deterioration in the cost-of-sales ratio, higher raw material prices and other costs, and higher research and development expenses as clinical trials progressed. In the Animal Health business, purchase prices for feed additives rose due to the weaker yen and geopolitical risks. In the Overseas business, procurement of active pharmaceutical ingredients from the Middle East for core products became difficult, among other factors.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥17,384 million (YoY -1.5%) |
| Operating profit | ¥711 million (YoY -51.4%) |
| Ordinary income | ¥817 million (YoY -48.7%) |
| Profit attributable to owners of the parent | ¥533 million (YoY -57.5%) |
| Net income per share | ¥18.78 |
| Equity ratio | End of the current fiscal period 64.4 / End of previous period 62.6 |
| Total assets | ¥109,905 million |
| Net assets | ¥77,296 million |
| Full-year earnings forecast | Net Sales ¥73,000 million (YoY +2.6%) / Operating profit ¥6,200 million (YoY +6.3%) / Ordinary income ¥6,100 million (YoY +7.7%) / Net income ¥4,800 million (YoY -11.5%) |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥60 → ¥65（+8.3%） |
| Segment revenue | Pharmaceuticals Business ¥14,484 million (YoY -0.2%), Animal Health Business ¥1,952 million (YoY +6.1%), Overseas Business ¥908 million (YoY -25.9%), Other businesses (outside reportable segments) ¥38 million (YoY -33.4%) |
| Segment profit | Pharmaceuticals Business ¥1,132 million (YoY -33.3%), Animal Health Business ¥44 million (YoY -65.4%), Overseas Business ¥-35 million, Other businesses (outside reportable segments) ¥-8 million |
| Depreciation and amortization | ¥697 million |
| Breakdown of extraordinary income (loss) | Extraordinary income None (-) / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 28,763,199 shares |
| Treasury Shares at Period-End | 367,085 shares |
| Factors Behind Changes in Business Performance | Ongoing drug price revisions, higher manufacturing costs, a deterioration in the cost-of-sales ratio, higher raw material prices and other costs, and higher research and development expenses as clinical trials progressed. In the Animal Health business, purchase prices for feed additives rose due to the weaker yen and geopolitical risks. In the Overseas business, procurement of active pharmaceutical ingredients from the Middle East for core products became difficult, among other factors. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue declined due to the effects of ongoing drug price revisions and higher manufacturing costs. On the earnings side, the cost-of-sales ratio deteriorated, raw material prices and other costs increased, and research and development expenses rose as clinical trials progressed.